PlainRecalls
FDA Drug Critical Class I Terminated

Paliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, NDC: 0591-3693-19

Reported: July 19, 2017 Initiated: May 31, 2017 #D-0960-2017

Product Description

Paliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, NDC: 0591-3693-19

Reason for Recall

Failed Dissolution Specifications: Drug release test result, obtained during routine 9-month stability testing, which was below specification for one tablet. Teva cannot at this time exclude the potential for additional tablets to be below specification.

Details

Recalling Firm
Teva Pharmaceuticals
Units Affected
360 bottles
Distribution
Nationwide in the US
Location
Horsham, PA

Frequently Asked Questions

What product was recalled?
Paliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, NDC: 0591-3693-19. Recalled by Teva Pharmaceuticals. Units affected: 360 bottles.
Why was this product recalled?
Failed Dissolution Specifications: Drug release test result, obtained during routine 9-month stability testing, which was below specification for one tablet. Teva cannot at this time exclude the potential for additional tablets to be below specification.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 19, 2017. Severity: Critical. Recall number: D-0960-2017.